Nuvectis Pharma (NVCT) Cash from Operations (2021 - 2026)
Nuvectis Pharma (NVCT) posted Cash from Operations of 6511000.0 for Q1 2026, down 63.84% sequentially from 3974000.0 in Q4 2025, and down 55.99% YoY from 14794182.91 in Q1 2025.
Nuvectis Pharma (NVCT) Cash from Operations (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Cash from Operations for 6 years, with the latest figure at 6511000.0 in Q1 2026.
- Quarterly Cash from Operations fell 55.99% year-over-year to 6511000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 18346000.0 (down 52.08% YoY) and the FY2025 annual result came in at 16009000.0, down 30.72% from the prior year.
- Cash from Operations slipped to 6511000.0 in Q1 2026 per NVCT's latest filing, from 3974000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2404000.0 in Q3 2024 and troughed at 6511000.0 in Q1 2026.
- A 5-year average of 3781176.47 and a median of 3850000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations tumbled 229.52% in 2022, then soared 35.97% in 2024.
- Over 5 years, Cash from Operations stood at 3516000.0 in 2022, then declined by 9.5% to 3850000.0 in 2023, then surged by 35.97% to 2465000.0 in 2024, then sank by 61.22% to 3974000.0 in 2025, then tumbled by 63.84% to 6511000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 6511000.0, 3974000.0, and 4494000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | -4.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.53 Mn |
| Jun 30, 2026 | -4.53 Mn |
| Mar 31, 2026 | -6.51 Mn |
| Mar 31, 2026 | -6.51 Mn |
| Dec 31, 2025 | -3.97 Mn |
| Dec 31, 2025 | -3.97 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Jun 30, 2025 | -3.37 Mn |
| Jun 30, 2025 | -3.37 Mn |
| Mar 31, 2025 | -4.17 Mn |
| Mar 31, 2025 | -4.17 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Mar 31, 2024 | -4.36 Mn |